timothy sykes logo
Celcuity Stock Surges on Positive Phase 3 Results and Analyst Upgrades Thumbnail
G Google News

Celcuity Stock Surges on Positive Phase 3 Results and Analyst Upgrades

MATT MONACO•UPDATED JUN. 15, 2026, 5:10 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Celcuity Inc.’s stock surged up by 8.21% following promising news on advancements in cancer diagnosis technology.

Key Highlights from Recent Developments

  • Celcuity’s stock jumped over 42% on October 20, 2025, fueled by the announcement of promising Phase 3 trial results for gedatolisib in treating advanced breast cancer.
  • Stifel boosted its price target for Celcuity shares from $68 to $115, influenced by optimistic updates from the company’s recent Q3 conference and discussions about the U.S. market potential for VIKTORIA-1.
  • Craig-Hallum also raised its forecast for the stock, highlighting the robustness of Celcuity’s financial performance and its consistent progress in achieving key clinical milestones.

Healthcare industry expert:

Analyst sentiment – positive

Market Position & Fundamentals: Celcuity (CELC) is currently positioned within the biotechnology sector, focused on cancer treatment mechanisms. Financially, the company’s fundamentals indicate significant challenges. Key ratios show a concerning profitability trend with negative ebit (-39.21M) and ebitda (-38.39M) margins, and a substantial operating loss. Valuation ratios like a price-to-book ratio of 82.22 and price-to-cashflow of -25.20 suggest heavy market overvaluation relative to its financial strength. Despite a robust current ratio of 12.3 hinting at strong liquidity, a long-term debt-to-capital of 0.73 and negative returns on assets and equity underscore fiscal instability. Notably, Celcuity’s enterprise value stands at $4.15 billion, indicating market confidence possibly bolstered by robust R&D advancements rather than current fiscal performance. However, net losses from continuing operations and negative free cash flow reflect underlying operational inefficiencies, warranting cautious optimism.

Technical Analysis & Trading Strategy: Recent trading patterns in Celcuity’s stock reveal a strong upward trend, with a significant breakout noted in the last sessions, closing at $93.06 after starting the week at $76.7. This uptrend is underscored by increasing trading volumes, suggesting strong buying interest. The stock saw a notable jump mid-week between $85.15 to $92.68, pushing through several resistance levels which now turn to support. Current technical indicators support a bullish outlook with a recommendation to buy on pullbacks to the $86-$88 range, optimizing within this newly established support zone. Anticipate momentum to continue towards the revised targets of $108, backed by both fundamental catalysts and technical precedence, although vigilance over volatility is advised given the stock’s recent sharp appreciation.

Catalysts & Outlook: Recent positive updates have provided significant momentum for Celcuity. The company has reported better-than-expected Phase 3 trial data for its experimental drug gedatolisib, notably improving progression-free survival in breast cancer, positioning it as potentially a new treatment standard. Consequently, leading analysts have revised price targets upward, now suggesting a range between $95 and $115, reinforcing market optimism. Compared to Healthcare and Biotechnology benchmarks, CELC outpaces peers via these clinical advancements. The Stifel and Craig-Hallum updates further validate Celcuity’s potential, drawing investor interest focused on its innovative pipeline. Resistance levels of $115 should be monitored as potential profit-taking points, whereas the company’s substantial equity value denotes long-term growth prospects. Overall, the sentiment is positive, given the robust clinical pipeline and recent strategic financial influx.

Candlestick Chart

More Breaking News

Weekly Update Nov 10 – Nov 14, 2025: On Saturday, November 15, 2025 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 8.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The recent financial metrics of Celcuity Inc. reflect a mix of strategic resilience and forward momentum, despite reporting a Q3 adjusted loss of $0.78 per share, outperforming the anticipated loss of $0.96 per share. The company’s cash flow statements indicate strong operational and financial flexibility, supported by substantial financing activities that amassed $330.325M, signifying a robust financial backbone against the backdrop of a $44.813M net income deficit.

Recent gains in Celcuity’s stock, which escaladed from $76.7 to over $93.06 between November 10 and November 14, 2025, signify positive investor sentiment driven by clinical breakthroughs and increased earnings expectations. These developments coincide with a substantial price-to-book ratio of 82.22, indicating potential overvaluation when juxtaposed against a backdrop of negative profitability metrics such as an ROE fluctuating around -122.04%.

In light of new data, Celcuity is gearing towards transformative growth, propelled by a reinforced financial strategy that entails smarter debt management with total liabilities balanced at approximately $359M versus total equity of around $116.963M. The market’s optimistic response is further underscored by extensive trial expansions in the PIK3CA mutant cohort within the VIKTORIA-1 clinical initiative, which are pivotal to future growth trajectories.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”